Elicera Therapeutics AB (ELIC) Stock Overview

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform. The company was incorporated in 2014 and is based in Gothenburg, Sweden.